Aishwarya Sahasrabudhe

mTOR signaling contributes to system-driven rhythmic gene expression in mouse liver

Aishwarya Sahasrabudhe, Chanté R. Guy, Audrey Jacq, Chieh-Wen Ho et autres

Rhythmic gene expression is essential to the daily organization of biological processes. While cycling transcriptomes are regulated by circadian clocks present in nearly every cell, accumulating evidence indicates that they can also be initiated by rhythmic food-driven systemic signals independently of circadian …

us (code pays fourni par la source)

Untargeted global metabolomic profiling across the 24-hour day in mouse liver under three different feeding paradigms: Nighttime feeding, Arrhythmic feeding and Arrhythmic feeding with AZD8055 administration at night

Aishwarya Sahasrabudhe, Jérôme S. Menet

Untargeted global metabolomic profiling from mouse liver across the 24-hour day. Liver samples were collected at 6 time points (ZT 2, 6, 10, 14, 18, 22) 4 hours apart; after different feeding paradigms or treatment conditions. The 3 groups were- night-restricted feeding …

TNF-α signaling drives myeloid skewing and clonal expansion of stem and progenitor cells in RUNX1-familial platelet disorder

Mona Mohammadhosseini, Aishwarya Sahasrabudhe, Luiza H. Ostrowski, John McClatchy et autres

Not available.

us (code pays fourni par la source)

A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder

Leticia Campoverde, Warren C. Fiskus, Jillian K. Mullin, Hiam Abdel-Salam et autres

Abstract Background: Familial Platelet Disorder with germline RUNX1 mutation (RUNX1-FPD) is a rare inherited syndrome characterized by thrombocytopenia, qualitative platelet dysfunction, and an estimated 40% lifetime risk of hematologic malignancies, including myelodysplastic syndrome, acute myeloid leukemia, and lymphoid neoplasms. RUNX1-mutant hematopoietic stem …

us (code pays fourni par la source)

Supplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.

Supplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** …

Supplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with …

Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) …

Supplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.

Supplemental Table S1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Patient and disease characteristics for Beat AML RNAseq cohort (N = 228)

Supplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, …

Supplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis Andrew Lachowiez, Maël Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier et autres

RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.